Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3254936 | 0.89 | HSD11B1 (0.59) | HSD11B1MEN1KMT2ACCKBRPOLB | |
| SCHEMBL5830794 | 0.85 | GAA (0.45) | HSD11B1ALPLMEN1KMT2ACCKBR | |
| SCHEMBL3256644 | 0.84 | HSD11B1 (0.50) | HSD11B1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5831852 | 0.83 | HSD11B1 (0.44) | HSD11B1ALPLMEN1KMT2ACCKBR | |
| SCHEMBL3625053 | 0.83 | HSD11B1 (0.61) | HSD11B1ALPLMEN1KMT2ACCKBR | |
| SCHEMBL3254939 | 0.81 | HSD11B1 (0.66) | HSD11B1MEN1KMT2ACCKBRPOLB | |
| SCHEMBL6626832 | 0.80 | CCKBR (0.44) | HSD11B1ALPLMEN1KMT2ACCKBR | |
| SCHEMBL3255959 | 0.80 | HSD11B1 (0.83) | HSD11B1MEN1KMT2ACCKBRPOLB | |
| SCHEMBL6700302 | 0.79 | CCKBR (0.43) | HSD11B1ALPLMEN1KMT2ACCKBR | |
| SCHEMBL3255071 | 0.78 | HSD11B1 (0.49) | HSD11B1KMT2APOLBSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | claimed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | claimed |
| WO-2004112782-A1 | NEW USE V | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| EP-1461325-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | claimed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| WO-2003043999-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | claimed |
| EP-1461325-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| US-7671051-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7094792-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-08-22 | — | — | US | disclosed |
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | BIOVITRUM AB | 2005-11-10 | — | — | US | disclosed |
| WO-2004112782-A1 | NEW USE V | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1461325-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003043999-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250776-A1 | Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885ALPL 770/4885MEN1 808/4885 |
| US-20030130318-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885ALPL 461/4885MEN1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.